Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial

Silber, Sigmund; Windecker, Stephan; Vranckx, Pascal; Serruys, Patrick W; RESOLUTE All Comers investigators, (2011). Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet, 377(9773), pp. 1241-7. London: Elsevier 10.1016/S0140-6736(11)60395-4

Full text not available from this repository. (Request a copy)

In the RESOLUTE All Comers trial, the Resolute zotarolimus-eluting stent was non-inferior to the Xience V everolimus-eluting stent for the primary stent-related endpoint of target lesion failure (cardiac death, target vessel myocardial infarction, and ischaemia-driven target lesion revascularisation) at 1 year. However, data for long-term safety and efficacy from randomised studies of new generation drug-eluting coronary stents in patients treated in routine clinical practice are scarce. We report the prespecified 2-year clinical outcomes from the RESOLUTE All Comers trial.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Windecker, Stephan

ISSN:

0140-6736

Publisher:

Elsevier

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:21

Last Modified:

17 Mar 2015 19:29

Publisher DOI:

10.1016/S0140-6736(11)60395-4

PubMed ID:

21459430

Web of Science ID:

000289597300030

URI:

https://boris.unibe.ch/id/eprint/7231 (FactScience: 212419)

Actions (login required)

Edit item Edit item
Provide Feedback